ABOUT US
In 2008, Professor Esam H. Alhamad established The Interstitial (ILD) and Pulmonary Hypertension (PH) Center at King Saud University Medical City. The center is made of a multidisciplinary team for patients with pulmonary fibrosis and pulmonary hypertension. Our team comprise of highly dedicated multidisciplinary physicians (lung specialists, chest radiologists, pathologists, thoracic surgeons and rheumatologists), nurses and support staff who apply state-of-the-art, comprehensive and prompt evaluations and treatment recommendations. We are dedicated to providing continuous education and support to patients and their families on a daily basis. Simultaneously, our education sessions on pulmonary fibrosis and pulmonary hypertension are constantly present for physicians and other healthcare providers to access.
Our ILD and PH center are committed to improving the lives of patients within the Kingdom and wider region by prioritizing patient care, education and research. The research we conduct is set with the aims of attaining new cutting edge discoveries and knowledge in ILD for academic and societal benefits. In addition, we are not only dedicated to a mission of the highest quality and compassion of patient care but also to provide the best training to future pulmonary physicians, medical students, nurses and respiratory therapists. Our goal is to produce a unique environment that harmoniously integrates ILD diagnosis, management and research to patient and family education, future pulmonologists and associated healthcare provider training.
OUR MISSION
To improve the lives of patients who suffer from pulmonary fibrosis and pulmonary hypertension in the kingdom of Saudi Arabia and wider region by providing a state of the art care of compassion and quality.
To train and monitor future pulmonologists and associated health care providers who will become involved in the care taking of patients with pulmonary fibrosis and pulmonary hypertension.
To dedicate research to discovering new knowledge about Pulmonary fibrosis and pulmonary hypertension.
WHAT DO WE TREAT?
-
Idiopathic Pulmonary Fibrosis
-
Autoimmune-related Interstitial Lung Disease
-
Sarcoidosis
-
Hypersensitivity Pneumonitis
-
Chronic Eosinophilic Pneumonia
-
Pulmonary Hypertension
We hold multidisciplinary ILD meetings twice a month to evaluate, promptly diagnose and provide effective treatment. The various cases present are discussed and evaluated by physicians who come from varying specialties (pulmonology, Radiology, pathology, thoracic surgery, rheumatology) in which since 2012, a total of 1200 interstitial lung cases were examined and efficiently diagnosed through specific plans of action.
Moreover, our physicians are highly experienced in prescribing and managing drug therapy, including nintedanib and pirfenidone for idiopathic pulmonary fibrosis patients while simultaneously experienced with immunomodulatory and biological therapies for sarcoidosis and autoimmune lung diseases.
PUBLICATION
We are committed to discovering new knowledge about interstitial lung disease and pulmonary hypertension through research, some example of ILD & PH center publication:
- Clinical significance of minor salivary gland biopsy in patients with idiopathic interstitial pneumonia
- Clinical characteristics, comorbidities, and outcomes in patients with idiopathic pulmonary fibrosis
- Predictors of mortality in interstitial lung disease patients without pulmonary hypertension
- Physiological predictors of survival in patients with sarcoidosis-associated pulmonary hypertension: results from an international registry
- Clinical features of sarcoidosis associated pulmonary hypertension: Results of a multi-national registry.
- Rapid detection of circulating fibrocytes by flowcytometry in idiopathic pulmonary fibrosis
- Autoimmune symptoms in idiopathic pulmonary fibrosis: clinical significance.
- Cytokine gene polymorphisms and serum cytokine levels in patients with idiopathic pulmonary fibrosis.
- Clinical characteristics and survival in idiopathic pulmonary fibrosis and connective tissue disease-associated usual interstitial pneumonia.
- Bone mineral density in patients with interstitial lung disease.
- Comparison of three groups of patients with usual interstitial pneumonia.
- Interstitial lung diseases in Saudi Arabia: A single-center study.
- Prediction of pulmonary hypertension in patients with or without interstitial lung disease: reliability of CT findings.
- Pulmonary hypertension in Saudi Arabia: A single center experience.
- Pulmonary hypertension in end-stage renal disease and post renal transplantation patients.